1st Edition
Alternative Splicing and Cancer
Preface
1. Alternative Splicing and Human Diseases
Mukesh Tanwar
2. Mechanism of RNA Splicing
Tabasum Ashraf, Humaira Shah, Rouf Maqbool, Auqib Manzoor and Ashraf Dar
3. Alternative Splicing: A New Cancer Hallmark
Mohd Younis Rather, Ajaz Ahmad Waza, Yasmeena Hassan and Sabhiya Majid
4. Deregulated Spliceosome and Splice Variants in Cancers
Farheen Naz
5. Deregulated Oncogenic Signaling Pathway(s) and Alternative Splicing
Bhawana and Pratyusha Vavilala
6. Alternative Splicing and Metastasis
Bilal A. Naikoo and Muzafar A. Macha
7. Role of Splice Variant of Pyruvate Kinase M2 (PKM2) in Cancer Metabolism
Mohd Amir, Ata Abbas, Saleem Javed, Saleh Alfuraih and Rais Ansari
8. Alternative Splicing and Immune Surveillance
Moumita Roy
9. Therapeutic Targeting of Alternative Splicing in Cancers
Sabra Parveen, Bilal Rah, Waseem Akram, Shahid Ali, Abdul Basit Baba, Shahnawaz A. Wani, Amrita Bhat, Itty Sethi and Gh. Rasool Bhat
10. Alternative Splicing in Cancer Drug Resistance
Ashna Gupta, Ravi Chauhan, Tarang Sharma, Muzafar A. Macha, Tariq Masoodi, Ammira S. Al-Shabeeb Akil, Ajaz A. Bhat and Mayank Singh
11. A Systematic Evaluation of Alternative Splicing and Cancer: A Review
Amrita Bhat, Ruchi Shah and Rakesh Kumar
Index
Biography
Muzafar A. Macha, currently an Assistant Professor and Ramalingaswami Fellow at Watson-Crick Centre for Molecular Medicine, IUST, Kashmir, India, possesses a strong background in Biochemistry, Head and Neck Cancers (HNCs), and therapeutic modalities development. He previously served as a postdoctoral fellow and later as an Assistant Professor at the University of Nebraska Medical Centre (UNMC), leading an independent HNC research group. His notable contributions, recognized with multiple awards, include the identification of deregulated signaling pathways and innovative therapeutic strategies, published in esteemed journals.
Ajaz A. Bhat, a staff scientist at Sidra Medicine, Qatar, has an extensive background in peptide-based vaccine development, deregulated signaling pathways, and drug targets for various cancers. After earning his Ph.D. from AIIMS, India, he undertook postdoctoral training at Vanderbilt University Medical School, USA, expanding his understanding of colorectal, gastric, and esophageal cancers. His high-impact research, published in prestigious journals, earned him recognition as an outstanding researcher, and he actively serves on several immunology and cancer societies' editorial and review boards.
Surinder Kumar Batra, Chair of the Biochemistry and Molecular Biology Department at the University of Nebraska Medical Center (UNMC), USA, and Associate Director at Buffett Cancer Center, is renowned for his work on pancreatic cancer pathogenesis. His research focuses on mucins, glycoproteins with potential diagnostic and therapeutic applications. He has developed several genetically engineered models for cancer progression and received US patents on diagnostics and antibodies. With over 400 international peer-reviewed publications, he has trained 100+ scholars.
